Gene, Cell and Tissue

Published by: Kowsar

cGMP Phosphodiesterases (cGMP PDEs) As Therapeutic Targets in Cancer

Ramin Saravani 1 , * and Hamid Reza Galavi 1
Authors Information
1 Cellular and Molecular Research Center and Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Article information
  • Gene, Cell and Tissue: April 2017, 4 (2); e12336
  • Published Online: April 30, 2017
  • Article Type: Letter
  • Received: April 22, 2017
  • Accepted: April 29, 2017
  • DOI: 10.5812/gct.12336

To Cite: Saravani R, Galavi H R. cGMP Phosphodiesterases (cGMP PDEs) As Therapeutic Targets in Cancer, Gene Cell Tissue. 2017 ; 4(2):e12336. doi: 10.5812/gct.12336.

Copyright © 2017, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
References
  • 1. Rehmann H, Wittinghofer A, Bos JL. Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol. 2007; 8(1): 63-73[DOI][PubMed]
  • 2. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res. 2007; 100(3): 309-27[DOI][PubMed]
  • 3. Saravani R, Galavi HR, Shahraki A. Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468. Breast Cancer (Auckl). 2017; 11: 1.1782234176902E+15[DOI][PubMed]
  • 4. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015; 147: 12-21[DOI][PubMed]
  • 5. Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012; 43(6): 470-5[DOI][PubMed]
  • 6. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood. 2003; 101(1): 265-9[DOI][PubMed]
  • 7. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005; 94(2): 336-50[DOI][PubMed]
  • 8. Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal. 2002; 14(1): 45-51[DOI][PubMed]
  • 9. Saravani R, Karami-Tehrani F, Hashemi M, Aghaei M, Edalat R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif. 2012; 45(3): 199-206[DOI][PubMed]
  • 10. Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling. Mol Cancer Ther. 2013; 12(9): 1848-59[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments